Full Text View
Tabular View
No Study Results Posted
Related Studies
Anonymous Testing of Pathology Specimens for BRCA Mutations in Ashkenazi Jewish Individuals Who Have Cancer
This study is currently recruiting participants.
Verified by Memorial Sloan-Kettering Cancer Center, December 2008
First Received: December 22, 2007   Last Updated: December 9, 2008   History of Changes
Sponsored by: Memorial Sloan-Kettering Cancer Center
Information provided by: Memorial Sloan-Kettering Cancer Center
ClinicalTrials.gov Identifier: NCT00588263
  Purpose

The intent of the proposed study is to describe the prevalence of the most common recurring mutations in BRCA1 and BRCA2, blmAsh , and the A636P MSH2 mutation among Ashkenazi Jewish individuals with a variety of cancer diagnoses. If a substantial proportion of these samples contain such mutations, future patients presenting with these diseases may wish to undergo genetic counseling and, if appropriate, formal genetic testing. The benefit from such a process would pertain mainly to the families of these individuals.


Condition
Extrahepatic Bile Duct Cancer
Gallbladder Cancer
Gastric Cancer
Lung Cancer
Melanoma
Non-Hodgkin's Lymphoma
Uterine Cancer
CORPUS UTERI,ENDOMETRIUM
Lung
Ovary

MedlinePlus related topics: Cancer Gallbladder Cancer Lung Cancer Lymphoma Melanoma Stomach Cancer Uterine Cancer
U.S. FDA Resources
Study Type: Observational
Study Design: Cohort, Prospective
Official Title: Anonymous Testing of Pathology Specimens for BRCA Mutations in Ashkenazi Jewish Individual With Cancer

Further study details as provided by Memorial Sloan-Kettering Cancer Center:

Biospecimen Retention:   Samples With DNA

Biospecimen Description:

Blocks or extracted DNA from patients who have identified themselves as Jewish will be obtained and a determination will be made as to whether there is adequate material to proceed without exhausting the block or extracted DNA.

Four unstained sections (research specimens) or paraffin "curls" will be cut from each block. In those cases where a block containing normal resection margin or any other biopsy of normal tissue are available, tissue will be cut from this block so as to preserve tumor tissue for later investigators. It is not necessary for sections to be reviewed to confirm that tumor is present in the section, since any germline DNA is adequate for this analysis.


Estimated Enrollment: 1905
Study Start Date: July 2000
Estimated Study Completion Date: July 2010
Estimated Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
Detailed Description:

Germline mutations in the genes BRCA1 and BRCA2 have been demonstrated in the majority of hereditary breast and ovarian cancer families. The increased risk to develop both breast and ovarian cancer associated with inheriting a BRCA1 or BRCA2 mutation has been well established. It has also been suggested that is an overrepresentation of other cancers such as colon, prostate and pancreatic cancer present in BRCA1 or BRCA2 families. Population specific mutations in BRCA1 and BRCA2 have been identified. In the Ashkenazi Jewish population, 3 specific mutations have been seen in 2% of the population. This study will anonymously screen archived tissue samples of Ashkenazi Jewish individuals diagnosed with cancer between 1993 and 1996 at MSKCC for the three founder mutations seen in the Ashkenazi Jewish population. Results will be stratified by tumor type and compared with the population frequency to determine whether individuals inheriting mutations in BRCA1 or BRCA2 may have an increased risk to develop other cancers, in addition to breast and ovarian cancer. This information will be useful in helping to identify individuals who may benefit from genetic counseling and possibly genetic testing who to date are not typically referred. It will also be useful in developing high-risk cancer screening strategies and determining appropriate options for prophylactic surgery.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Cases will be identified in one of two ways. Pathology records will be reviewed for the years 1985-present. All patients with diagnoses of pancreatic cancer, uterine cancer,lymphoma, melanoma, cancer of the gallbladder and bile duct, stomach cancer, brain cancer, ovarian cancer, colon cancer, head and neck cancer, lung cancer and breast cancer(including DCIS) from 1985 to the present at MSKCC will be identified.

Criteria

Inclusion Criteria:

  • Diagnosis of cancer made at MSKCC or collaborating institutions, AND
  • Tissue block of tumor or normal margin or extracted DNA available for study and sufficient material present to allow study without exhausting block or DNA,
  • Individual self-identified as Jewish on intake.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00588263

Contacts
Contact: Kenneth Offit, M.D. offitk@mskcc.org

Locations
United States, New York
Memorial Sloan-Kettering Cancer Center Recruiting
New York, New York, United States, 10065
Contact: Kenneth Offit, MD     212-434-5149     offitk@mskcc.org    
Principal Investigator: Kenneth Offit, M.D.            
Sponsors and Collaborators
Memorial Sloan-Kettering Cancer Center
Investigators
Principal Investigator: Kenneth Offit, M.D. Memorial Sloan-Kettering Cancer Center
  More Information

Additional Information:
No publications provided

Responsible Party: Memorial Sloan-Kettering Cancer Center ( Kenneth Offit, M.D. )
Study ID Numbers: 00-087
Study First Received: December 22, 2007
Last Updated: December 9, 2008
ClinicalTrials.gov Identifier: NCT00588263     History of Changes
Health Authority: United States: Institutional Review Board

Keywords provided by Memorial Sloan-Kettering Cancer Center:
Ashkenazi Jewish
Cancer

Study placed in the following topic categories:
Gallbladder Diseases
Thoracic Neoplasms
Gastrointestinal Diseases
Urogenital Neoplasms
Bile Duct Cancer, Extrahepatic
Melanoma
Lymphoma, Small Cleaved-cell, Diffuse
Genital Diseases, Female
Stomach Diseases
Respiratory Tract Diseases
Lung Neoplasms
Nevus, Pigmented
Biliary Tract Diseases
Stomach Neoplasms
Neoplasms, Germ Cell and Embryonal
Neuroepithelioma
Uterine Neoplasms
Lymphoma
Digestive System Neoplasms
Biliary Tract Neoplasms
Immunoproliferative Disorders
Genital Neoplasms, Female
Uterine Diseases
Neuroendocrine Tumors
Gall Bladder Cancer
Lymphatic Diseases
Neuroectodermal Tumors
Digestive System Diseases
Bile Duct Diseases
Lung Diseases

Additional relevant MeSH terms:
Gallbladder Diseases
Thoracic Neoplasms
Gastrointestinal Diseases
Neoplasms, Nerve Tissue
Urogenital Neoplasms
Melanoma
Genital Diseases, Female
Stomach Diseases
Neoplasms by Site
Respiratory Tract Diseases
Lung Neoplasms
Neoplasms, Germ Cell and Embryonal
Biliary Tract Diseases
Stomach Neoplasms
Uterine Neoplasms
Nevi and Melanomas
Lymphoma
Respiratory Tract Neoplasms
Digestive System Neoplasms
Biliary Tract Neoplasms
Neoplasms by Histologic Type
Immunoproliferative Disorders
Immune System Diseases
Genital Neoplasms, Female
Uterine Diseases
Neuroendocrine Tumors
Neuroectodermal Tumors
Lymphatic Diseases
Neoplasms
Digestive System Diseases

ClinicalTrials.gov processed this record on May 07, 2009